Clinical trial intelligence topics

ALS

Validated public reports are available for this disease area.

Alzheimer's disease

Validated public reports are available for this disease area.

AML

Validated public reports are available for this disease area.

Acne Vulgaris

Validated public reports are available for this disease area.

Obesity

Validated public reports are available for this disease area.

Type 2 Diabetes

Validated public reports are available for this disease area.

MASH / NASH

Validated public reports are available for this disease area.

Solid Tumors

Validated public reports are available for this disease area.

Breast Cancer

Validated public reports are available for this disease area.

Lung Cancer

Validated public reports are available for this disease area.

Multiple Myeloma

Validated public reports are available for this disease area.

Heart Failure

Validated public reports are available for this disease area.

Parkinson's Disease

Validated public reports are available for this disease area.

Atopic Dermatitis

Validated public reports are available for this disease area.

Asthma

Validated public reports are available for this disease area.

Major Depressive Disorder

Validated public reports are available for this disease area.

behavioral intervention

cell therapy

combination therapy

gene therapy

medical device

microbiome therapy

monoclonal antibody

protein therapy

RNA therapy

small molecule

vaccine

[225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)

[89Zr]Zr-DFO-AP-101 is designed to target misfolded SOD1 protein associated with amyotrophic lateral sclerosis (ALS), facilitating visualization of CNS pathology through PET imaging.

10˚C deceased donor kidney storage using Traferox XPort

100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162, Placebo

18F-Florbetaben (Neuraceq®) PET/MRI

3d printed mask

3DOF balance board robotic platform group, Conventional Rehabilitation

5-HT3 receptor antagonist (ondansetron)

6% Bemotrizinol (BEMT)

a/LCI-OCT imaging probe, esophageal biopsy

AAV2-GDNF gene therapy for Parkinson's Disease

ABC008 targets immune modulation in Inclusion Body Myositis (IBM) by potentially influencing the depletion of killer cell lectin-like receptor G1 (KLRG1)+ cells.

Abemaciclib, Trastuzumab Emtansine

Ablative carbon dioxide laser therapy targeting vulvovaginal atrophy (VVA) and genitourinary syndrome of menopause (GSM) symptoms.

ABT-450/r/ABT-267, Placebo

Acceptance and Commitment Therapy (ACT) as a psychological intervention for caregivers of individuals with dementia.

Acceptance and commitment therapy + app, Acceptance and commitment therapy

Acetaminophen

Acetaminophen, Ibuprofen

Acetylcholinesterase (Ach-E) inhibitors: Galantamine and Donepezil

Acetylcholinesterase (AChE) inhibition via Donepezil, a piperidine derivative.

Acetylcholinesterase (AChE) inhibition via donepezil, a reversible inhibitor of the enzyme, enhancing cholinergic neurotransmission.

Acetylcholinesterase inhibition (Donepezil/Aricept)

Acetylcholinesterase inhibition via Donepezil Hydrochloride, a reversible inhibitor of the enzyme acetylcholinesterase, enhancing cholinergic neurotransmission.

Actimmune Registry

Active Mattress Cover, Placebo Mattress Cover

Acute Lymphoblastic Leukaemia (ALL) treatment with a focus on risk stratification and innovative therapies including Inotuzumab ozogamicin and Blinatumomab.

Acute ST Elevation Myocardial Infarction

Adavosertib

Adenosine

Adenosine A3 receptor (A3AR)

Adenosine, Adenosine Mono Phosphate (AMP)

ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID

aerobic treadmill exercise

Affective lability and emotion regulation in bipolar disorder

AGA2115

AGA2115, Placebo

AKB-6548

Alendronate Effervescent Oral Tablet

Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.

Almonertinib, chemotherapy

ALN-XDH, Placebo

Alpha-1 Antitrypsin Deficiency (AATD) - associated lung disease, utilizing AAV and CRISPR/Cas9 gene editing technology.

Alpha-2C adrenoceptor (AR)

ALS-L1023, placebo

Alzheimer's Disease (AD) management through behavioral intervention during bathing.

Amantadine, Ribavirin, Oseltamivir, Oseltamivir

AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks

AMG 162, Placebo

AMG 355, Pembrolizumab

Amifampridine phosphate (3,4-Diaminopyridine Phosphate) acts as a potassium channel blocker, enhancing the release of acetylcholine at the neuromuscular junction, thereby improving neuromuscular transmission.

Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams per milliliter (MG/ML), PET/CT Scan

Amorphous Calcium Carbonate (ACC) as a potential adjunct therapy for Castrate Resistant Prostate Cancer (CRPC) with Bone Metastasis, focusing on skeletal health and pain management.

AMX0035 targets neuroprotective mechanisms through the combination of Tauroursodeoxycholic Acid and Sodium Phenylbutyrate, aimed at reducing neuronal cell death and promoting cellular resilience in Amyotrophic Lateral Sclerosis (ALS).

Amyloid production in the brain related to Alzheimer's dementia.

An abdominal binder

Androgen Receptor (AR) modulation via PROTAC technology

Androgen Receptor (AR) via Proteolysis-targeting Chimeras (PROTACs)

Androgen receptor signaling pathway modulation

Androgen receptors and androgen synthesis pathways (triptorelin and flutamide).